SP0183, LD 565, item 2, ‘An Act Regarding the Prescribing and Dispensing of Naloxone Hydrochloride by Pharmacists’

Amend the bill by striking out the title and substituting the following:

‘An Act Regarding the Prescribing and Dispensing of Naloxone Hydrochloride by Pharmacists’

Amend the bill by striking out everything after the enacting clause and inserting the following:

‘Sec. 1. 22 MRSA §2353, sub-§1, ¶D, as enacted by PL 2015, c. 508, §1, is amended to read:

D. "Pharmacist" means a pharmacist authorized to prescribe and dispense naloxone hydrochloride pursuant to Title 32, section 13815.

Sec. 2. 22 MRSA §2353, sub-§2, ¶A-1, as enacted by PL 2015, c. 508, §2, is amended to read:

A-1. A pharmacist may prescribe and dispense naloxone hydrochloride in accordance with protocols established under Title 32, section 13815 to an individual at risk of experiencing an opioid-related drug overdose.

Sec. 3. 22 MRSA §2353, sub-§2, ¶A-2, as enacted by PL 2017, c. 249, §1, is repealed.

Sec. 4. 22 MRSA §2353, sub-§2, ¶C-1, as enacted by PL 2015, c. 508, §2, is amended to read:

C-1. A pharmacist may prescribe and dispense naloxone hydrochloride in accordance with protocols established under Title 32, section 13815 to a member of an individual's immediate family or a friend of the individual or to another person in a position to assist the individual if the individual is at risk of experiencing an opioid-related drug overdose.

Sec. 5. 22 MRSA §2353, sub-§2, ¶C-2, as enacted by PL 2017, c. 249, §1, is repealed.

Sec. 6. 32 MRSA §13815, sub-§1, as enacted by PL 2017, c. 249, §2, is repealed.

Sec. 7. 32 MRSA §13815, sub-§2, as enacted by PL 2017, c. 249, §2, is amended to read:

2. Rules for prescribing and dispensing naloxone hydrochloride. The board by rule shall establish standards for authorizing pharmacists to prescribe and dispense naloxone hydrochloride in accordance with Title 22, section 2353, subsection 2, paragraphs A-2 and C-2 A-1 and C-1. The rules must establish adequate training requirements and protocols for prescribing and dispensing naloxone hydrochloride when there is no prescription drug order, standing order or collaborative practice agreement authorizing naloxone hydrochloride to be dispensed to the intended recipient. Rules adopted under this subsection are routine technical rules as defined in Title 5, chapter 375, subchapter 2-A. A pharmacist authorized by the board pursuant to this subsection to prescribe and dispense naloxone hydrochloride may prescribe and dispense naloxone hydrochloride in accordance with Title 22, section 2353, subsection 2, paragraphs A-2 and C-2 A-1 and C-1.

This subsection is repealed July 1, 2019.

Sec. 8. Maine Revised Statutes headnote amended; revision clause. In the Maine Revised Statutes, Title 32, chapter 117, subchapter 11-A, in the subchapter headnote, the words "dispensing of naloxone hydrochloride" are amended to read "prescribing and dispensing of naloxone hydrochloride" and the Revisor of Statutes shall implement this revision when updating, publishing or republishing the statutes.’

summary

This amendment replaces the bill, which is a concept draft. It repeals the provisions of Public Law 2017, chapter 249 that prevent pharmacists from prescribing and dispensing naloxone hydrochloride after July 1, 2019 to an individual at risk of an overdose or to a family member or friend of an individual at risk of an overdose.

FISCAL NOTE REQUIRED

(See attached)

SP0183 LD 565	Session - 128th Maine Legislature C "A", Filing Number S-372, Sponsored by		LR 1847 Item 2
	Bill Tracking, Additional Documents	Chamber Status

Bill Tracking		Chamber Status
Amendments	Testimony, Public Hearings & Work Sessions		Committee Information for this Bill
Other Documents			Title & Section

Search Bill Text		Search Bill Status
Bill Directory	Current Committees		Legislative Information
Download MS-Word, Printed PDF		Maine Legislature

Office of Legislative Information 100 State House Station Augusta, ME 04333		voice: (207) 287-1692 fax: (207) 287-1580 tty: (207) 287-6826
Word Viewer for Windows		Disclaimer